Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cleveland Biolabs Inc (NASDAQ:CBLI)

2.21
Delayed Data
As of May 27
 -0.01 / -0.45%
Today’s Change
1.92
Today|||52-Week Range
7.24
-36.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$22.7M

Company Description

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company, with a focus on oncology and acute radiation syndrome drug development. It is engaged in the research, development and commercialization of products that have the potential to treat cancer which reduces death from total body irradiation and counteract the toxic effects of radio and chemotherapies for oncology patients. The company has designed two oppositely-directed general therapeutic concepts: temporary and reversible suppression of apoptosis in normal cells to protect healthy tissues from stress-induced damage using compounds categorized as Protectans; and reactivation of apoptosis in tumor cells to eliminate cancer using compounds categorized as Curaxins. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY.

Contact Information

Cleveland BioLabs, Inc.
73 High Street
Buffalo New York 14203
P:(716) 849-6810
Investor Relations:
(917) 375-2935

Employees

Shareholders

Other institutional4.91%
Individual stakeholders1.19%
Mutual fund holders1.01%

Top Executives

Yakov KoganChief Executive Officer
Langdon L. MillerPresident & Chief Medical Officer
Andrei V. GudkovChief Scientific Officer
Rachel LevineVice President-Investor Relations
Michelle C. RossSenior VP-Public Health & Government Affairs